[Disease modifying anti-rheumatic drugs (DMARDs): an overview].
Kawabata
Daisuke
D
Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine.
Mimori
Tsuneyo
T
D018501:Antirheumatic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D001578:Benzopyrans; D003545:Cysteine / Q000031:analogs & derivatives*; D019317:Evidence-Based Medicine; D006052:Gold Sodium Thiomalate; D006801:Humans; D007555:Isoxazoles; D000077339:Leflunomide; D015201:Meta-Analysis as Topic; D008727:Methotrexate; D016032:Randomized Controlled Trials as Topic; D012460:Sulfasalazine; D013449:Sulfonamides
D018501:Antirheumatic Agents; D001578:Benzopyrans; D007555:Isoxazoles; D013449:Sulfonamides; D006052:Gold Sodium Thiomalate; C077313:T 614; D012460:Sulfasalazine; D000077339:Leflunomide; D003545:Cysteine; C026535:bucillamine; D008727:Methotrexate